Loestrin transaction gets further FTC scrutiny
Executive Summary
FTC has requested additional information on Barr's proposed acquisition of rights to Galen's Loestrin oral contraceptive line (1"The Pink Sheet" Sept. 15, 2003, p. 37). Barr had hoped to close the deal by Feb. 1; the company is "unable to determine the impact" of FTC's request for additional information...